Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1

Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial

Published:2024-05 Issue:5 Volume:11 Page:e345-e357
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Gladwin Mark T,Gordeuk Victor R,Desai Payal C,Minniti Caterina,Novelli Enrico M,Morris Claudia R,Ataga Kenneth I,De Castro Laura,Curtis Susanna A,El Rassi Fuad,Ford Hubert James,Harrington Thomas,Klings Elizabeth S,Lanzkron Sophie,Liles Darla,Little Jane,Nero Alecia,Smith Wally,Taylor James G,Baptiste Ayanna,Hagar Ward,Kanter Julie,Kinzie Amy,Martin Temeia,Rafique Amina,Telen Marilyn J,Lalama Christina M,Kato Gregory J,Abebe Kaleab Z

Funder

Bayer HealthCare Pharmaceuticals Inc

Publisher

Elsevier BV

Reference36 articles.

1. Pathophysiology of sickle cell disease;Sundd;Annu Rev Pathol,2019

2. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes;Kato;Blood Rev,2007

3. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease;Reiter;Nat Med,2002

4. Platelet extracellular vesicles drive inflammasome-IL-1β-dependent lung injury in sickle cell disease;Vats;Am J Respir Crit Care Med,2020

5. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC;Drawz;Clin J Am Soc Nephrol,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Riociguat shows remarkable safety but underwhelming activity in patients with sickle cell disease;The Lancet Haematology;2024-05